Bortezomib, Thalidomide, and Dexamethasone (VTD) Induction Results in Better Overall Survival than Adriamycin, Thalidomide, and Dexamethasone (ATD) Induction in Previously UntreatedMyeloma Patients Eligible for Transplants.
Chen JF et al. Acta Haematol. 2017 May 5;137(4):207-208. doi: 10.1159/000471839. [Epub ahead of print].

Successful treatment of patients with newly diagnosed/untreated light chain multiple myeloma with a combination of bendamustine, prednisone and bortezomib (BPV).
Tessenow H et al. J Cancer Res Clin Oncol. 2017 May 22. doi: 10.1007/s00432-017-2439-x. [Epub ahead of print].

Mobilization of Hematopoietic Stem Cells for Hematopoietic Cells Autologous Transplantation with Use of Plerixafor.
Gawroński K et al. Ann Transplant. 2017 May 12;22:296-302.

Efficacy and safety of plerixafor for the mobilization/collection of peripheral hematopoietic stem cells for autologous transplantation in Japanese patients with multiple myeloma.
Ri M et al. Int J Hematol. 2017 May 19. doi: 10.1007/s12185-017-2255-8. [Epub ahead of print].

High-dose gemcitabine, busulfan, and melphalan for autologous stem-cell transplant in patients with relapsed or refractory myeloma: a phase 2 trial and matched-pair comparison with melphalan.
Nieto Y et al. Lancet Haematol. 2017 May 15. pii: S2352-3026(17)30080-7. doi: 10.1016/S2352-3026(17)30080-7. [Epub ahead of print].

Gemcitabine, busulfan, and melphalan conditioning for autologous stem-cell transplants inmultiple myeloma.
Gahrton G. Lancet Haematol. 2017 May 15. pii: S2352-3026(17)30063-7. doi: 10.1016/S2352-3026(17)30063-7. [Epub ahead of print].

Outcome of autologous hematopoietic stem cell transplantation in refractory multiple myeloma.
Veltri LW et al. Cancer. 2017 May 17. doi: 10.1002/cncr.30770. [Epub ahead of print].

Circularly permuted TRAIL plus thalidomide and dexamethasone versus thalidomide and dexamethasone for relapsed/refractory multiple myeloma: a phase 2 study.
Leng Y et al. Cancer Chemother Pharmacol. 2017 Jun;79(6):1141-1149. doi: 10.1007/s00280-017-3310-0. Epub 2017 May 12.

Haploidentical Allogeneic Hematopoietic Cell Transplantation for Multiple Myeloma Using Post Transplant Cyclophosphamide GVHD Prophylaxis.
Castagna L et al. Biol Blood Marrow Transplant. 2017 May 9. pii: S1083-8791(17)30453-6. doi: 10.1016/j.bbmt.2017.05.006. [Epub ahead of print].

Follow-up of patients with refractory or relapsed multiple myeloma after allogeneic hematopoietic cell transplantation.
Schneidawind C et al. Clin Transplant. 2017 May 3. doi: 10.1111/ctr.12994. [Epub ahead of print].

Daratumumab Monotherapy Compared With Historical Control Data in Heavily Pretreated and Highly Refractory Patients With Multiple Myeloma: An Adjusted Treatment Comparison.
Usmani SZ et al. Am J Hematol. 2017 May 5. doi: 10.1002/ajh.24781. [Epub ahead of print].